Inhibition of Wnt could improve antigen presentation, CD8+ T-cell infiltration, and anti-tumor macrophage differentiation, which may yield a more promising scenario for employing immunotherapy in the ER+ breast cancer setting. This evidence concerns the gene CD8A and breast carcinoma.